Evaluation of the QTc prolongation risk of deutetrabenazine
Objective: To assess QTc prolongation risk of deutetrabenazine and its active metabolites by conducting exposure-QTc interval modeling, and to predict QTc prolongation in both CYP2D6…Risk of Tardive Dyskinesia in Patients with Tic Disorders: Preliminary Results
Objective: To determine the relative risk of tardive dyskinesia in patients with tic disorders by comparing three clinical populations: i) patients with tic disorders without…Reanalysis of a Patient-Reported Outcome (Tardive Dyskinesia Impact Scale) Shows Positive Results
Objective: To reanalyze the Tardive Dyskinesia Impact Scale (TDIS) and assess its potential utility in future TD studies. Background: TD is a persistent and potentially…Impacts of Tardive Dyskinesia (TD) Symptoms on Patients: Analysis of a TD-Specific Patient-Reported Outcome
Objective: To understand the impact of tardive dyskinesia (TD) symptoms on patients, confirm the appropriateness of the Tardive Dyskinesia Impact Scale (TDIS) as a patient-reported…Patterns of Improvement with Valbenazine in Patients with Tardive Dyskinesia
Objective: To characterize different patterns of improvement with valbenazine (VBZ) in patients with tardive dyskinesia (TD) using Abnormal Involuntary Movement Scale (AIMS) data from KINECT…The Impact of Antipsychotic Dose Reduction Within a Medicare Population
Objective: To analyze the burden of antipsychotic (AP) dose reduction in Medicare patients with schizophrenia (SZ). Background: Tardive dyskinesia (TD) develops in patients treated with…Deutetrabenazine Reduces Involuntary Movements in Patients Most Severely Impacted by Tardive Dyskinesia in a 3-year Open-Label Extension Trial
Objective: To evaluate the efficacy of deutetrabenazine (DTBZ) in reducing TD in the most severely impacted patients using data from an ongoing open-label extension (OLE)…Long-Term Treatment With Deutetrabenazine (DTBZ) Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From the Completed, 3-year Open-Label Extension (OLE) Study
Objective: To evaluate long-term efficacy and safety of DTBZ in patients with TD by examining change from baseline in Abnormal Involuntary Movement Scale (AIMS) scores…Long-term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia
Objective: To assess the long-term safety and efficacy of deutetrabenazine in younger (<55 years) and older (≥55 years) patients with tardive dyskinesia (TD). Background: TD…Prospective investigation of the frequency of tardive syndromes in outpatients attending two specialist psychiatry hospitals in Lagos, Nigeria
Objective: To determine the frequency and profile of TS in persons on antipsychotics attending tertiary psychiatry hospitals. Background: The term tardive syndrome (TS) encompasses the…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 8
- Next Page »